Patient Input

Patient Input


 

We want as many people as possible living with HIV and hepatitis C to have their voices heard by drug regulators.

 

When drugs are submitted by manufacturers to Health Canada for a Notice of Compliance (NOC), CADTH puts out a call to all patient groups to submit input regarding the drug seeking a NOC.

 

CTAC regularly contributes to the CADTH Common Drug Review Patient Input process for a number of HIV and hepatitis C drugs.

 

The experiences and feedback from patients is key in informing the recommendations CADTH makes to publicly funded drug plans throughout Canada.

 

To sign up for notifications about future patient input consultations please email info@ctac.ca. You can learn more about the Common Drug Review via this engaging video produced by CTAC.


Previous Patient Input Consultations

 

You can view previous patient input consultations at www.youtube.com/ctactalks

SOFOSBUVIR/VELPATASVIR/VOXILAPREVIR (SOF/VEL/VOX)


This hepatitis C medication is pan-genotypic and has been researched as an option for various patient populations including people living with HIV/HCV co-infection, people with past treatment failure, people living with cirrhosis and people who have had liver or renal transplants. This webinar discussed the clinical trials supporting this new drug’s examination by Canada’s Common Drug Review. If you have experience of using SOF/VEL/VOX and would be happy to share your experiences please do get in touch with Amanda Fletcher at amanda@ctac.ca.

GLECAPREVIR/PIBRENTASVIR (G/P)


This hepatitis C medication is pan-genotypic and has been researched as an option for various patient populations including people living with HIV/HCV co-infection, people with past treatment failure, people living with cirrhosis and people who have had liver or renal transplants